**REVIEW**

3535  Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios  
Katoch S, Sharma V, Patial V

3555  Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions  
Li YG, Yu ZJ, Li A, Ren ZG

**MINIREVIEWS**

3573  Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities  
da Fonseca LG, Araujo RLC

3586  Update on endoscopic ultrasound-guided liver biopsy  
Rangwani S, Ardeshna DR, Mumtaz K, Kelly SG, Han SY, Krishna SG

3595  Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?  
Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA

3608  Potassium-competitive acid blockers and gastroesophageal reflux disease  
Leowattana W, Leowattana T

3620  Making the case for multidisciplinary pediatric aerodigestive programs  
Kanotra SP, Weiner R, Rahhal R

3627  Therapeutic potential of mesenchymal stem cells in the treatment of acute liver failure  
Harrell CR, Pavlovic D, Djonov V, Volarevic V

3637  Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment  
Nishimoto A

**ORIGINAL ARTICLE**

**Basic Study**

3644  Mechanism of electroacupuncture and herb-partitioned moxibustion on ulcerative colitis animal model: A study based on proteomics  
**Contents**

**World Journal of Gastroenterology**

**Weekly Volume 28 Number 28 July 28, 2022**

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Retrospective Study</strong></td>
<td>How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study</td>
<td>3666</td>
</tr>
<tr>
<td></td>
<td>Kwon Y, Kim ES, Choe YH, Kim MJ</td>
<td></td>
</tr>
<tr>
<td><strong>Observational Study</strong></td>
<td>Gastric mucosal precancerous lesions in Helicobacter pylori-infected pediatric patients in central China: A single-center, retrospective investigation</td>
<td>3682</td>
</tr>
<tr>
<td></td>
<td>Yu M, Ma J, Song XX, Shao QQ, Yu XC, Khan MN, Qi YB, Hu RB, Wei PR, Xiao W, Jia BL, Cheng YB, Kong LF, Chen CL, Ding SZ</td>
<td></td>
</tr>
<tr>
<td><strong>Scientometrics</strong></td>
<td>Global research on Clostridium difficile-associated diarrhoea: A visualized study</td>
<td>3720</td>
</tr>
<tr>
<td></td>
<td>Zyoud SH</td>
<td></td>
</tr>
<tr>
<td><strong>Case Report</strong></td>
<td>Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report</td>
<td>3732</td>
</tr>
<tr>
<td></td>
<td>Tanaka T, Sakai A, Tsujimae M, Yamada Y, Kobayashi T, Masuda A, Kodama Y</td>
<td></td>
</tr>
<tr>
<td><strong>Letter to the Editor</strong></td>
<td>Prednisolone induced pneumatosis coli and pneumoperitoneum</td>
<td>3739</td>
</tr>
<tr>
<td></td>
<td>Goh SSN, Shelat V</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Is patient satisfaction sufficient to validate endoscopic anti-reflux treatments?</td>
<td>3743</td>
</tr>
<tr>
<td></td>
<td>Bortolotti M</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endoluminal vacuum-assisted therapy as a treatment for anastomotic leakage in colorectal surgery</td>
<td>3747</td>
</tr>
<tr>
<td></td>
<td>Chiarello MM, Bianchi V, Fransvea P, Brisinda G</td>
<td></td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Giovanna Ferraioli, MD, FAIUM, Researcher, Department of Clinical Surgical, Diagnostic and Pediatric Sciences, Medical School University of Pavia, Viale Brambilla 74, Pavia 27100, Italy. giovanna.ferraioli@unipv.it

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS
http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
July 28, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?

Ângelo Z Mattos, Jose D Debes, Arndt Vogel, Marco Arrese, Xavier Revelo, Tales Henrique S Pase, Muriel Manica, Angelo A Mattos

Abstract

Hepatocellular carcinoma (HCC) is among the most common cancers and it is a major cause of cancer-related deaths. Non-alcoholic fatty liver disease (NAFLD) affects approximately one fourth of individuals worldwide and it is becoming one of the most important causes of HCC. The pathogenic mechanisms leading to NAFLD-related HCC are complex and not completely understood. However, metabolic, fibrogenic, oncogenic, inflammatory and immunological pathways seem to be involved. First-line therapy of advanced HCC has recently undergone major changes, since the combination of atezolizumab and bevacizumab was
proven to increase survival when compared to sorafenib. Other immune-oncology drugs are also demonstrating promising results in patients with advanced HCC when compared to traditional systemic therapy. However, initial studies raised concerns that the advantages of immunotherapy might depend on the underlying liver disease, which seems to be particularly important in NAFLD-related HCC, as these tumors might not benefit from it. This article will review the mechanisms of NAFLD-related hepatocarcinogenesis, with an emphasis on its immune aspects, the efficacy of traditional systemic therapy for advanced NAFLD-related HCC, and the most recent data on the role of immunotherapy for this specific group of patients, showing that the management of this condition should be individualized and that a general recommendation cannot be made at this time.

**Key Words**: Non-alcoholic fatty liver disease; Hepatocellular carcinoma; Hepatocarcinogenesis; Immunology; Immunotherapy; Tyrosine kinase inhibitors

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip**: Non-alcoholic fatty liver disease (NAFLD) is an important cause of hepatocellular carcinoma (HCC). While the treatment of advanced HCC has recently undergone a revolution led by immunotherapy, concerns have been raised that NAFLD-related HCC might not respond well to these new therapies. This review will approach the pathophysiology of NAFLD-related liver cancer, the evidence on traditional systemic treatments and the most recent data on immunotherapy for this particular group of patients, showing that the management of this condition should be individualized.

**INTRODUCTION**

The incidence of liver cancer worldwide was 11.6/100000 individuals in 2020 and its mortality rate reached 10.7/100000 in the same year, making it the sixth most common cancer and the second cause of cancer-related mortality[1]. Furthermore, it is estimated that its incidence rate will continue to increase until 2030[2]. Hepatocellular carcinoma (HCC) is by far the most common among primary liver cancers[3,4].

Non-alcoholic fatty liver disease (NAFLD) has a striking prevalence of 25% worldwide[5], which highlights its relevance as an underlying cause of HCC[6]. In the year of 2019, for instance, NAFLD was estimated to be associated with 36300 new cases of HCC, as well as with 34700 HCC-related deaths[7]. As it would be expected, the burden of NAFLD as a cause of HCC seems to be growing. It is estimated that the age-standardized incidence rate of NAFLD-related liver cancer will raise from 0.92 to 1.18/100000 individuals between 2018 and 2030[2]. Moreover, while a multinational cohort study demonstrated that NAFLD was responsible for 9% of HCC cases followed between 2005 and 2015 in South America (an area with high prevalence of NAFLD)[8], the same group verified that it was responsible for 34% of cases followed between 2019 and 2020[9].

Cirrhosis in general predisposes to HCC, and the annual incidence of HCC in patients with NAFLD-related cirrhosis ranges between 0.5% and 2.6%[10-13]. However, some specific mechanisms associated with NAFLD, which will be further discussed in this article, also allow for the development of HCC in the absence of cirrhosis, making NAFLD itself etiologically associated to hepatocarcinogenesis[6,14-16]. According to a meta-analysis, approximately 38% of NAFLD-related HCCs would develop in non-cirrhotic settings[17]. Still, it must be highlighted that the risk of developing HCC is much lower in patients with NAFLD who do not have cirrhosis than in those with NAFLD-related cirrhosis, as it has been recently shown in another meta-analysis (incidence of 0.03 vs 3.78/100 person-years)[18].

Significant progress has been recently made in the treatment of advanced HCC, when immunotherapy was proven superior to the systemic therapy used for over a decade[19,20]. Table 1 shows a summary of the most important randomized controlled trials on systemic therapy for advanced HCC.

Nevertheless, initial studies raised concerns that the advantages of immunotherapy might depend on the underlying liver disease, and that patients with NAFLD-related HCC might benefit less from it[21,22]. Considering the epidemiological importance of NAFLD-related HCC, this article aims to review the
mechanisms behind NAFLD-related hepatocarcinogenesis, with an emphasis on its immune aspects, the knowledge gathered over the years on the efficacy of traditional systemic therapy for advanced NAFLD-related HCC, and the most up-to-date evidence on the role of immunotherapy for this specific group of patients.

### PATHOPHYSIOLOGY OF NAFLD-RELATED HCC

The underlying pathogenic mechanisms leading to NAFLD-related HCC are complex and not completely understood\[10,23,24\]. Metabolic dysfunction as well as inflammatory, fibrogenic and oncogenic pathways are involved, which are in turn modulated by a myriad of factors. These include, among others, genetic and epigenetic changes, different degrees of dysregulation of multiorgan metabolic and endocrine signaling, altered immunologic responses and changes in gut microbiota\[24, 25\].

A disturbed systemic metabolic milieu characterized mainly by insulin resistance and a low-grade inflammatory state seems to be a key in promoting carcinogenesis in a fat-laden liver. Both type 2 diabetes and obesity are known risk factors for NAFLD-related HCC, which may act additively with other metabolic syndrome traits (i.e., dyslipidemia and hypertension) in increasing the risk of HCC development\[25,26\]. However, the precise molecular mechanisms underpinning the connection between metabolic dysfunction and HCC remain incompletely understood. Metabolic dysfunction-related changes in lipid metabolism (including uncontrolled lipolysis in adipose tissue leading to fatty acid overflow towards the liver and stimulation of hepatic de novo lipogenesis) lead to hepatocyte lipid overload that, in turn, triggers some compensatory adaptations such as downregulation of carnitine palmitoyltransferase 2, which may promote hepatocarcinogenesis. Accumulation of acylcarnitine has been suggested as a potential mechanism in this regard\[27\]. Also, changes in sterol regulatory element-binding proteins transcription factors, key regulators of sterol and fatty acid biosynthesis, may contribute through interaction with tumor suppressor genes such as p53\[28\].

---

#### Table 1 Summary of randomized controlled trials on systemic therapy for advanced hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Interventions</th>
<th>Mechanisms of action</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Llovet et al</td>
<td>Sorafenib × placebo</td>
<td>TKI × placebo</td>
<td>Increased OS with sorafenib</td>
</tr>
<tr>
<td>Cheng et al</td>
<td>Sorafenib × placebo</td>
<td>TKI × placebo</td>
<td>Increased OS with sorafenib</td>
</tr>
<tr>
<td>Bruix et al</td>
<td>Regorafenib × placebo</td>
<td>TKI × placebo</td>
<td>Increased OS with regorafenib</td>
</tr>
<tr>
<td>Kudo et al</td>
<td>Lenvatinib × sorafenib</td>
<td>TKI × TKI</td>
<td>Non-inferior OS</td>
</tr>
<tr>
<td>Abou-Alfa et al</td>
<td>Cabozantinib × placebo</td>
<td>TKI × placebo</td>
<td>Increased OS with cabozantinib</td>
</tr>
<tr>
<td>Zhu et al</td>
<td>Ramucirumab × placebo</td>
<td>Anti-VEGF receptor 2 × placebo</td>
<td>Increased OS with ramucirumab</td>
</tr>
<tr>
<td>Yau et al</td>
<td>Nivolumab × sorafenib</td>
<td>Anti-PD-1 × TKI</td>
<td>No increase in OS(^4)</td>
</tr>
<tr>
<td>Finn et al</td>
<td>Pembrolizumab × placebo</td>
<td>Anti-PD-L1 × placebo</td>
<td>No increase in OS(^4)</td>
</tr>
<tr>
<td>Finn et al</td>
<td>Atezolizumab + bevacizumab × sorafenib</td>
<td>Anti-PD-L1 + anti-VEGF × TKI</td>
<td>Increased OS with atezolizumab + bevacizumab</td>
</tr>
<tr>
<td>Kelley et al</td>
<td>Atezolizumab + cabozantinib × sorafenib</td>
<td>Anti-PD-L1 + TKI × TKI</td>
<td>No increase in OS(^4)</td>
</tr>
<tr>
<td>Abou-Alfa et al</td>
<td>Tremelimumab + durvalumab × durvalumab × sorafenib</td>
<td>Anti-CTLA-4 + anti-PD-L1 × anti-PD-L1 × TKI</td>
<td>Increased OS with tremelimumab + durvalumab (× sorafenib). Non-inferior OS with durvalumab (× sorafenib)</td>
</tr>
</tbody>
</table>

\(^1\)2nd line treatment.  
\(^2\)2nd or 3rd line treatment.  
\(^3\)Individuals with alpha-fetoprotein ≥ 400 ng/mL.  
\(^4\)Primary endpoint not reached.  
Importantly, lipid overload also leads to the occurrence of oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, cell injury and cell death, all triggering inflammatory responses and activating fibrogenic processes[29]. Moreover, numerous signaling pathways are also dysregulated, including activation of interleukin (IL)-6/Janus kinase/signal transducer and activator of transcription (STAT) pathway and insulin-like growth factor, among others[30].

Of note, in the setting of a chronic inflammatory microenvironment, death of hepatocytes by different mechanisms (necrosis, apoptosis, pyroptosis and other forms of the cell death) determines a compensatory hepatocyte proliferation. This proliferative response is associated with genetic and epigenetic changes that play a pivotal role in hepatocarcinogenesis. Among these genetic changes, different studies have identified mutations in the telomerase reverse transcriptase promoter, p53 gene and wingless-related integration site (Wnt)/β-catenin signaling pathway genes as the most consistent genetic changes during HCC development[26]. Finally, epigenetic modifications have been shown to be involved in HCC progression in the context of NAFLD. A broad range of changes in chromatin remodeling, histone alterations, DNA methylation, and noncoding RNA expression has been described and reviewed recently[31]. Such processes have diagnostic, prognostic, and therapeutic implications[32].

Experimental evidence generated in mouse models and some human data strongly suggest that altered gut microbiota may be an important contributing factor to HCC development in the setting of NAFLD/nonalcoholic steatohepatitis (NASH)[33]. The occurrence of dysbiosis is common in NAFLD/NASH, as well as in its commonly associated comorbidities, such as obesity and type 2 diabetes. Nevertheless, although microbiome changes have been characterized in different studies involving subjects with NASH or NAFLD-related cirrhosis, there is considerable variability across different reports, and only few studies have focused specifically on NAFLD-related HCC. Ponziani et al[34] showed that cirrhotic NAFLD-related HCC patients had a microbiome profile enriched in Bacteroidetes and Ruminococcaceae compared to patients with NAFLD-related cirrhosis without HCC[34]. This microbiota profile was associated with increased levels of some circulating pro-inflammatory cytokines. However, it remains unclear if this is just an epiphenomenon or has pathogenetic relevance.

Mechanistically, dysbiosis leads to altered intestinal permeability, which in turn contributes to hepatic inflammation via toll-like receptor 4 (TLR4) stimulation by bacterial derived products. Sustained hepatic inflammation triggered by this pathway can then contribute to hepatocarcinogenesis through multiple mechanisms[23]. Consistent with this proposed mechanism, TLR4 ablation has been shown to prevent HCC development in NASH models[35]. Additionally, changes in gut microbiota critically influence bile acid metabolism. Thus, animals fed with a NASH-promoting diet exhibit a change in their bile acid pool composition, which become enriched in secondary bile acids, particularly deoxycholic acid[33]. Moreover, microbiome changes may induce the transition of hepatic stellate cells (HSCs) in the stroma into a senescence-associated secretory phenotype, which are cells associated with suppression of antitumor immunity[36].

Specific genetic polymorphisms that influence NAFLD susceptibility and severity, such as patatin-like phospholipase domain containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 and membrane bound O-acetyltransferase domain containing 7, have been linked to a higher risk for NAFLD-related HCC[26]. Of these polymorphisms, the I148M variant of PNPLA3 is one of striking relevance in HCC development[37]. Carriage of this variant critically influences triacylglycerol remodeling in hepatocytes, and recent evidence shows that it also influences fibrogenesis and carcinogenesis by impairing retinol release from HSCs[38].

NAFLD-related HCC generally emerges in the setting of cirrhosis, but may arise also in a non-cirrhotic liver. Some pathways have been shown to play a role in this scenario. Increased STAT-3 signaling has been shown to be associated to the development of HCC independently of NASH and fibrosis. Also, disruption of circadian homeostasis has been shown to be related to HCC development independently of cirrhosis[39].

In summary, pathobiological mechanisms of hepatocarcinogenesis result from a complex interaction of the above-mentioned factors leading to uncontrolled proliferative responses, dysregulation of DNA-damage-response pathways, activation of survival signaling, angiogenesis, evasion of immune surveillance, genomic instability and ultimately to cancer development. It is likely that, in NAFLD patients, mechanisms leading to HCC vary from one subject to another given the heterogeneous population grouped under the acronym[40]. Precision medicine approaches based on advanced biomarkers may help identify those at higher risk of developing HCC in order to include them in surveillance programs or, once diagnosed, may allow treatment with targeted therapies.

**IMMUNE ASPECTS OF NAFLD-RELATED HCC**

Emerging evidence suggests that the chronic inflammatory process of NAFLD and NASH sets the basis for the development of HCC[41]. In addition, there seems to be a role for innate and adaptive immune cells in the pathogenesis of NAFLD-related HCC (Figure 1). However, the immune mechanisms that are specific to NAFLD as the underlying cause of HCC are largely unclear. For example, numerous studies have demonstrated the critical involvement of hepatic macrophages, including resident Kupffer cells...
Figure 1 Immune mechanisms in nonalcoholic fatty liver disease-related hepatocellular carcinoma pathogenesis. Studies using human specimens and mouse models have shown that activated non-alcoholic steatohepatitis-associated, programmed cell death protein 1+ CD8 T cells can cause non-specific cell death of hepatocytes and promote hepatocellular carcinoma development. T helper 17 cell-derived interleukin-17, immunoglobulin A-producing cells promote non-alcoholic steatohepatitis-derived hepatocellular carcinoma development, while an overall loss of CD4 T cells may increase tumor burden size. Bregs are abundant in hepatocellular carcinoma and promote disease progression, but are not specific to nonalcoholic fatty liver disease-related hepatocellular carcinoma. The role of tumor associated macrophages in the progression of nonalcoholic fatty liver disease-related hepatocellular carcinoma is unclear. Figure created in the Mind the Graph platform, available at www.mindthegraph.com. Th: T helper; PD-1: Programmed cell death protein 1; IL: Interleukin; Bregs: Regulatory B cells; IgA: Immunoglobulin A; CXCR6: C-X-C Motif Chemokine Receptor 6; TAM: Tumor associated macrophages.
and increase the susceptibility to HCC. In addition to T cells, emerging evidence suggests that immunoglobulin A (IgA)-producing B cells play a critical role in the progression of NAFLD-related HCC. In humans, the number of tumor-infiltrating B cells correlates with tumor progression[51]. Likewise, patients with HCC that have fewer tumor-infiltrating plasma cells present a better prognosis[52]. Feeding a high fat diet to major urinary protein-urokinase-type plasminogen activator transgenic mice, a reliable model of NAFLD-related HCC, instigates IgA-producing cells to interfere with the protective role of anti-tumor cytotoxic CD8 T cells[53]. The IgA positive B cells inhibit the activity of CD8 T cells through the expression of programmed death-ligand 1 (PD-L1) and the production of the immunosuppressive cytokine IL-10[53].

Regulatory B cells, a subset of B cells, can also inhibit anti-tumor immunity through IL-10 production and promote HCC growth through direct interactions with the tumor cells[54]. As B cells promote NAFLD through the production of pro-inflammatory cytokines and regulation of intrahepatic T cells in NASH[55], future studies are needed to clarify the precise role of liver B cells in NAFLD-related HCC.

### TRADITIONAL SYSTEMIC TREATMENT FOR ADVANCED NAFLD-RELATED HCC

Systemic therapy for HCC is relatively young in comparison to other cancers, becoming available only after 2007, with the arrival of sorafenib, a multikinase inhibitor that showed improved survival against placebo in both the SHARP and Asia-Pacific trials[56,57]. For 10 years, sorafenib was the only available systemic therapy for HCC, until the field expanded significantly over the last 5 years with trials showing benefit from regorafenib, lenvatinib, cabozantinib and ramucirumab[58-61]. All of these studies were performed on HCCs from multiple etiologies, but primarily viral hepatitis-related tumors.

Recently, attention has shifted to the importance of HCC etiology as a predictor of response to systemic therapy. This issue has been most evident in HCC immunotherapy, but potentially applies to other systemic therapies as well.

NAFLD-related HCC represents a unique conundrum for systemic therapy, as metabolic issues beyond that of HCC may play a role[62]. Individuals with NAFLD-related HCC are more likely to be obese, and are more likely to be on hormone-related medications, both of which could affect the pharmacokinetics of systemic therapy. Indeed, a small study showed that patients on sorafenib who were receiving metformin for diabetes mellitus had worse survival than those on insulin, regardless of the cause of HCC[63].

Due to the temporal dynamics of HCC systemic therapy in the last 15 years, most of the available data is from sorafenib studies. Sorafenib is known to perform best when used in patients with viral hepatitis-related HCC, particularly hepatitis C infection. However, most studies addressed hepatitis C vs alcohol-related HCC, or viral hepatitis vs other causes of HCC, clouding the understanding of the role of sorafenib in NAFLD-related HCC specifically[64-66]. An international study, presented only in abstract form, found similar overall survival (OS) in patients treated with sorafenib with NAFLD-related HCC vs other causes [hazard ratio (HR): 0.94, 95% confidence interval (CI): 0.76-1.16, \( P = 0.57 \)]. However, the NAFLD portion of the study included only 187 patients (3.5% of the total cohort), and further details are awaited with the full peer-reviewed version[67]. A recent retrospective subgroup analysis including 483 NAFLD-related HCC patients treated with sorafenib also found no significant difference in univariate analysis of survival between NAFLD and other etiologies (10.2 mo vs 12.3 mo; HR: 1.06; 95% CI: 0.83-1.34, \( P = 0.63 \))[68].

Information on NAFLD-related HCC for other non-immune forms of systemic therapy remains rather elusive, although very recent studies are shedding some light on the field. The initial trials for regorafenib (RESORCE), cabozantinib (CELESTIAL) and ramucirumab (REACH-2) included very limited numbers of patients with NAFLD-related HCC (6.6%, 9.3% and 7.9% respectively), and most subgroup analyses did not specifically evaluate NAFLD-related HCC[58-60]. The CELESTIAL trial for cabozantinib indicated benefit of the drug across all subgroups of etiologic factors and found no difference for OS between viral hepatitis-related HCC and other etiologies (HR: 0.76, 95% CI: 0.63-0.92 vs HR: 0.72, 95% CI: 0.54-0.96). However, the “other etiologies” group included all non-viral hepatitis-related tumors, with the NASH proportion conforming 43 patients. Also, this trial evaluated cabozantinib as second line therapy[58].

More recently, retrospective studies have evaluated lenvatinib in NAFLD-related HCC, suggesting an advantage for this multikinase inhibitor in this group of patients. A multicenter analysis of 236 NAFLD-related HCCs treated with lenvatinib (19% of the entire cohort) found a better OS for NAFLD-related HCC compared to other etiologies (22.2 mo vs 15.1 mo, HR: 0.69, 95% CI: 0.56-0.85, \( P = 0.0006 \))[68]. A Japanese study (also retrospective) of lenvatinib in unresectable tumors involving 103 NAFLD-related HCCs found no difference in OS compared to other etiologies, but the progression free survival (PFS) was better in the NAFLD group (median 9.3 mo vs 7.5 mo, \( P = 0.011 \))[69]. Furthermore, the retrospective multicenter ELEVATOR study, in which 200 patients were treated with lenvatinib, observed a similar survival in patients with viral and non-viral (NASH and alcoholic steatohepatitis) related HCC[70].

This early evidence suggests that sorafenib or cabozantinib are not particularly better (or worse) for NAFLD-related HCC, and that the use of lenvatinib might pose an advantage, with no specific data, so
far, for regorafenib. Nevertheless, it should be noted that better studies are needed in order to draw significant conclusions.

**IMMUNOTHERAPY FOR ADVANCED NAFLD-RELATED HCC**

In recent years, besides several tyrosine kinase inhibitors and a monoclonal antibody against vascular endothelial growth factor (VEGF) receptor-2 being added to the treatment armamentarium, immunotherapy with immune checkpoint blockers has been extensively investigated in patients with HCC[71]. Nivolumab, pembrolizumab, and the combination of nivolumab plus ipilimumab have been approved by the United States Food and Drug Administration (FDA) based on very promising phase II studies [72], but nivolumab and pembrolizumab failed to reach their primary endpoints in subsequent phase III trials in first- and second-line, respectively[73,74].

**Atezolizumab plus bevacizumab**

Overexpression of VEGF has been associated with liver cancer development and progression, and small phase II studies have shown modest anti-tumor efficacy of bevacizumab as monotherapy in advanced HCC[75]. In addition to the angiogenicic effects, there is increasing evidence that anti-VEGF therapies may enhance the efficacy of anti-PD-1 and anti-PD-L1 by reversing VEGF-mediated immunosuppression and promoting T-cell infiltration in tumors[76]. Based on these observations, the PD-L1 inhibitor atezolizumab was evaluated together with the VEGF inhibitor bevacizumab in the phase III IMBrave150 study. The combination significantly improved all efficacy endpoints with a statistically significant and clinically meaningful survival benefit compared to sorafenib[19,77]. Side effect profiles of the drugs were in line with their respective mechanism of action and no new safety signals were observed. Additionally, patient-reported outcomes revealed that deteriorations in quality of life were significantly delayed in the combination arm compared to the sorafenib arm[78]. The combination has been approved by the FDA and by the European Medicines Agency (EMA), and it is currently regarded as the standard of care in first-line therapy of advanced HCC.

**Atezolizumab plus cabozantinib**

In the COSMIC-312 trial, in which 837 patients with HCC were randomized to be treated with atezolizumab plus cabozantinib, sorafenib in monotherapy or cabozantinib in monotherapy (2:1:1), PFS was 6.8 mo for the group receiving combination therapy, compared to 4.2 mo for the group under sorafenib (HR: 0.63, 95%CI: 0.44-0.91, \(P = 0.0012\)). Regarding OS, an interim analysis did not demonstrate a significant difference between combination treatment and monotherapy with sorafenib (HR: 0.90, 95%CI: 0.69-1.18, \(P = 0.438\)). Finally, the interim analysis on the comparison between cabozantinib and sorafenib showed a tendency favoring cabozantinib regarding PFS (HR: 0.71, 95%CI: 0.51-1.01)[79].

**Dual checkpoint inhibition**

Two antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have been investigated in advanced HCC. The combination of nivolumab and ipilimumab has already shown improved OS in HCC patients in the phase I/II CheckMate040 study[80,81]. The pure immune-oncology (IO) combination achieved a high overall response rate with a promising OS of almost 23 mo. The most common immune related adverse events were rash, hepatitis, and adrenal insufficiency. Based on these results, the FDA approved nivolumab plus ipilimumab as second-line treatment for patients with advanced HCC previously treated with sorafenib. Currently, the checkmate 9DW study evaluates the efficacy of nivolumab plus ipilimumab compared to sorafenib or lenvatinib as first-line therapy.

Similar to ipilimumab, tremelimumab has also been studied as an anti-CTLA-4 antibody in HCC. Based on promising phase II data, the combination of durvalumab and tremelimumab was compared with durvalumab in monotherapy or sorafenib in monotherapy as first-line therapy for unresectable HCC in the HIMALAYA trial. Regarding the comparison between combination therapy and monotherapy with sorafenib, there was a significant improvement in OS favoring combination therapy (16.4 mo vs 13.8 mo, HR: 0.78, 95%CI: 0.65-0.92, \(P = 0.0035\)), and durvalumab plus tremelimumab may be approved by the FDA and EMA in the near future as an additional option for first-line treatment in HCC. Finally, monotherapy with durvalumab was noninferior to sorafenib regarding OS (HR: 0.86, 95%CI: 0.73-1.03)[82].

**Etiology of liver disease and immunotherapy**

A very recent study suggested that clinicians might need to consider the underlying liver disease for treatment selection in HCC. Pfister et al[21] provided provocative preclinical and limited clinical evidence that patients with NAFLD-related HCC may benefit less from immune checkpoint inhibition than patients with viral hepatitis-related HCC. Regarding preclinical data, authors evaluated immunotherapy in mice with NAFLD-related HCC. Despite the hepatic abundance of PD-1 positive CD8 T cells with features of exhaustion and effector functions in mice with NASH, which might be suggestive of a good response to immunotherapy, none of the pre-existing tumors regressed with treatment, and there
was evidence indicating that immunotherapy could even play a role in hepatocarcinogenesis in mice with NASH. In the same publication, a meta-analysis of three randomized controlled phase III trials failed to demonstrate evidence of survival improvement for patients with non-viral hepatitis-related HCC receiving immunotherapy. The authors also investigated a cohort of 130 HCC cases, in which 13 were NAFLD-related and had OS after immunotherapy of 5.4 mo, significantly lower than that of patients with HCCs related to other causes of liver disease (11.0 mo, \( P = 0.023 \)). Finally, authors validated these findings in yet another cohort of 118 individuals with HCC, in which 11 were NAFLD-related and had OS of 8.8 mo, while patients with HCC related to other causes of liver disease had OS of 17.7 mo (\( P = 0.034 \))[21]. Nevertheless, important remarks on this study have been made in an editorial, which highlighted that patients with NASH were not separated from those with other non-viral hepatitis etiologies of liver disease in the meta-analysis presented in the paper, and that the small number of patients evaluated in the cohorts must be kept in mind when considering their results[85].

In the same line, both the Checkmate-459 and the IMBrave150 trials found that HR for OS was worse in patients with non-viral hepatitis-related HCC compared with patients with viral hepatitis-related cancer. However, neither study distinguished between patients with NASH and alcoholic steatohepatitis. In addition, it should be noted that the poor HRs in the non-viral hepatitis group were not solely due to the shorter survival in the IO arm, but also to a surprisingly long survival in the sorafenib arm of both trials[19,84]. Similarly, in the COSMIC-312 trial, when a subgroup analysis on etiology of the underlying liver disease was performed, the benefit of atezolizumab plus cabozantinib on PFS seemed to be driven by the hepatitis B-related HCC group, and there was no significant difference between combination therapy and sorafenib for patients with non-viral hepatitis-related HCC (HR: 0.92, 95%CI: 0.60-1.41)[20].

Another recent meta-analysis of randomized controlled trials helped fuel this debate, when it also demonstrated that immune checkpoint inhibitors were significantly more effective for viral hepatitis-related HCCs than for tumors associated with other kinds of liver disease. On the other hand, the etiology of liver disease did not seem to interfere with the efficacy of tyrosine-kinase inhibitors or anti-VEGF therapies[22].

In contrast to these observations, underlying liver disease (viral hepatitis vs alcohol vs NASH) did not significantly impact PFS and OS in a recent real-world cohort treated with atezolizumab and bevacizumab[85]. Moreover, in the HIMALAYA trial, the benefit of the combination of durvalumab and tremelimumab on OS persisted in the subgroup analysis in patients with non-viral hepatitis-related HCC (HR: 0.74, 95%CI: 0.57-0.95)[82].

Perhaps the decision to start immunotherapy might be guided by prognostic biomarkers, rather than solely by the etiology of liver disease. Several predictive biomarkers for immunotherapy response have been proposed, including PD-L1 expression[86] and evidence of activated Wnt/β-catenin signaling[87], but currently no validated biomarker exists to guide treatment decisions in HCC patients undergoing immunotherapy. The recently proposed CRAFTY score (C reactive protein and alpha-fetoprotein in ImmunoTherapy) may be an easy-to-use tool to predict outcomes of patients undergoing immunotherapy for HCC, regardless of Child-Pugh class and performance status[88].

CONCLUSION

As the field moves forward, and with early evidence suggesting a potential decreased response of NAFLD-related HCC to immunotherapy, studies of non-immune systemic therapy for this group of patients should become more frequent and more robust. Moreover, randomized controlled trials evaluating immunotherapy in this particular group of patients are of the utmost importance. Multiple issues should be taken into account in such studies, including the strict definition of NAFLD, metabolic associated fatty liver disease or NASH, the heterogeneity of this group which includes lean NAFLD, NAFLD related to metabolic syndrome and others, as well as the impact of other co-morbidities and medication profiles.

FOOTNOTES

Author contributions: All authors contributed to this paper with conception of the manuscript, literature review and analysis, drafting and critical revision of the manuscript, and approval of the final version of the paper.

Supported by European-Latin American ESCALON Consortium, Funded By The EU Horizon 2020 Program, No. 825510; Robert Wood Johnson Foundation, Harold Amos Medical Faculty Development Program to JDD; University of Minnesota Academic Investment Research Program–AIRP Grant to JDD; Fondo Nacional de Ciencia y Tecnologia de Chilex to MA, No. FONDECYT-1191145; Agencia Nacional de Investigación y Desarrollo to MA, No. ANID-ACE 210009.

Conflict-of-interest statement: Dr. Mattos reports grants from EU Horizon 2020 program, grants from Robert Wood Johnson Foundation and grants from European-Latin American ESCALON Consortium, respectively.
Johnson Foundation, Harold Amos Medical Faculty Development Program, grants from Fondo Nacional de Ciencia y Tecnología de Chile and Comisión Nacional de Investigación, Ciencia y Tecnología, grants from University of Minnesota Academic Investment Research Program–AIRP grant, grants from Agencia Nacional de Investigación y Desarrollo (ANID ACE 210009), during the conduct of the study.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Brazil

ORCID number: Ângelo Z Mattos 0000-0002-3063-0199.

Corresponding Author’s Membership in Professional Societies: Federação Brasileira De Gastroenterologia.

S-Editor: Fan JR
L-Editor: A
P-Editor: Fan JR

REFERENCES


13 Amstree SM, Banrai BA, Sanyal AJ, Nauck MR. Hepatocellular carcinoma in non-alcoholic fatty liver disease and cirrhosis: a review. *Hepatology* 2021; 74 Suppl 1: 681A


17 Stine JG, Wentworth BI, Zimmett A, Rinella ME, Loombar R, Caldwell SH, Arko CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver
The PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated with obesity-induced gut microbial metabolite promotes liver cancer through senescence modulation of the HBP1-p53-Srebp1c pathway.


Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related death worldwide. Its incidence is expected to increase over the coming decades due to rising obesity rates and aging populations. The PNPLA3 gene encodes a lipase that plays a role in lipid metabolism. Recent studies have shown that the PNPLA3 rs738409 C >G polymorphism is associated with an increased risk of non-alcoholic fatty liver disease (NAFLD) and NASH, conditions that are major risk factors for the development of HCC.

The PNPLA3 variant has been linked to increased hepatic steatosis, ballooning, and fibrosis in patients with NAFLD, which are well-known risk factors for the development of HCC. In a study by Bruschi et al. (2014), the PNPLA3 variant was found to increase the risk of HCC in individuals with NAFLD, particularly in those with advanced liver fibrosis.

Moreover, the PNPLA3 variant has also been associated with changes in the gut microbiome, which play a crucial role in the development of HCC. In a study by Bruschi et al. (2014), the PNPLA3 variant was associated with changes in the gut microbiome, which play a crucial role in the development of HCC. The gut microbiome is known to produce a variety of metabolites that can affect the liver, and changes in the microbiome can lead to the development of HCC.

In summary, the PNPLA3 rs738409 C >G polymorphism is associated with an increased risk of HCC, particularly in patients with NAFLD. Future studies should focus on understanding the underlying mechanisms that link the PNPLA3 variant to the development of HCC, as well as exploring potential therapeutic targets for the prevention and treatment of HCC.
[PMID: 29041]


